Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry

Synapse

Volumn 53, Issue 1, 2004, Pages 36-43

  Preece, Nicholas E ^a   Houseman, J ^b   King, M D ^b   Weller, R O ^c   Williams, S R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

DWI; GABA; MRI; Vigabatrin

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN EDEMA; BRAIN INJURY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM; CONTROLLED STUDY; FRONTAL CORTEX; HISTOLOGY; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; MALE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY ANALYSIS; WHITE MATTER;

ANIMALS; ANTICONVULSANTS; BRAIN; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VIGABATRIN;

EID: 2542557399     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20038     Document Type: Article

References (39)

1. Barnes D, McDonald WI, Landon DN, Johnson G. 1988. The characterisation of experimental gliosis by quantitative NMR imaging. Brain 111:83-94.
2. Battaglioli G, Liu H, Martin DL. 2003. Kinetic differences between the isoforms of glutamate decarboxylase: implications for the regulation of GABA synthesis. J Neurochem 86:879-887.
3. Baulac M, Nordmann JP, Lanoe Y. 1998. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agent. Lancet 352:546.
4. 31P NMR spectroscopic study of rat brain in vivo. Magn Reson Med 31:660-667.
5. Brodie JD, Figueroa E, Dewey SL. 2003. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 50:261-265.
6. Butler WH. 1989. The neuropathology of VGB. Epilepsia 30:515-517.
7. Butler WH, Ford GP, Newberne JW. 1987. A study of the effects of VGB on the CNS and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 15:143-148.
8. Chang L, Cloak CC, Ernst T. 2003. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J Clin Psychiatry 64(Suppl 3):7-14.
9. Choi S, Silverman RB. 2002. Inactivation and inhibition of gamma-aminobutyric acid aminotransferase by conformationally restricted vigabatrin analogues. J Med Chem 45:4531-4539.
10. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. 2000. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 41:148-157.
11. Dijkstra CD, Dopp EA, Joling P, Kraal G. 1985. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2, and ED3. Immunology 54:589-599.
12. Fadda P, Scherma M, Fresu A, Collu M, Fratta W. 2003. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50:1-6.
13. Feldblum S, Erlander MG, Tobin AJ. 1993. Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles. J Neurosci Res 34:689-706.
14. B agonists and antagonists. Br J Pharmacol 141:152-162.
15. Gale K, Iadarola MJ. 1980. Seizure protection and increased nerve terminal GABA: delayed effects of GABA transaminase inhibition. Science 208:288-291.
16. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. 1990. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 18:225-238.
17. Jackson GD, Grunewald RA, Connelly A, Duncan JS. 1994a. Quantitative MR relaxometry study of effects of VGB on the brains of patients with epilepsy. Epilepsy Res 18:127-137.
18. Jackson GD, Williams SR, Weller RO, van Bruggen N, Preece NE, Williams SCR, Butler WH, Duncan JS. 1994b. VGB-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 18:57-66.
19. John RA, Rimmer EM, Williams J, Cole G, Fowler LJ, Richens A. 1987. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and VGB. Biochem Pharmacol 36:1467-1473.
20. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. 1977. VGB an inhibitor of GABA-T; effects on brain GABA metabolism in mice. J Neurochem 29:797-802.
21. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, Aanstoot HJ, Turck CW, Erlich H, Lennon V, et al. 1994. Higher autoantibody levels and recognition of a linear NH2-termina epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 180:595-606.
22. Le Bihan D, Bretton E, Lallemand D, Grenier P, Cabanais E, Laval-Jeantet M. 1986. MRI of intravoxel incoherent motions: application to diffusion and perfusion in neurological disorders. Radiology 161:401-407.
23. Mason GF, Martin DL, Martin SB, Manor D, Sibson NR, Patel A, Rothman DL, Behar KL. 2001. Decrease in GABA synthesis rate in rat cortex following GABA-transaminase inhibition correlates with the decrease in GAD(67) protein. Brain Res 914:81-91.
24. Mauguiere F, Chauvel P, Dewailly J, Dousse N. 1997. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 38:301-308.
25. 2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med 18:39-50.
26. Nanavati SM, Silverman RB. 1989. Design of potential anticonvulsant agents: mechanistic classification of GABA-aminotransferase inactivators. J Med Chem 32:2413-2421.
27. Perry TL, Kish SJ, Hansen S. 1979. Gamma-vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain. J Neurochem 32:1641-1645.
28. Peyster RG, Sussman NM, Hershey BL, Heydorn WE, Meyerson LR, Yarrington JT, Gibson JP. 1995. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 36:93-100.
29. Preece NE, Cerdan S. 1996. Metabolic precursors and compartmentation of cerebral GABA in vigabatrin-treated rats. J Neurochem 67:1718-1725.
30. Preece NE, Jackson GD, Houseman J, Duncan JS, Williams SR. 1994. NMR detection of elevated cortical GABA in the VGB-treated rat in vivo. Epilepsia 35:431-436.
31. Rimvall K, Martin DL. 1994. The level of GAD67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. J Neurochem 62:1375-1381.
32. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 90:5662-5666.
33. Schechter PJ, Hanke NF, Grove J, Huebert N, Sjoerdsma A. 1984. Biochemical and clinical effects of VGB in patients with epilepsy. Neurology 34:182-186.
34. Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL. 2000. Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study. Life Sci 66:169-173.
35. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. 2003. Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886-892.
36. Storici P, Capitani G, De Biase D, Moser M, John RA, Jansonius JN, Schirmer T. 1999. Crystal structure of GABA-aminotransferase, a target for antiepileptic drug therapy. Biochemistry 38:8628-8634.
37. Weiss KL, Schroeder CE, Kastin SJ, Gibson JP, Yarrington JT, Heydorn WE, McBride RG, Sussman NM, Arezzo JC. 1994. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 44:1944-1949.
38. Wimberger DM, Roberts TP, Barkovich J, Prayer LM, Moseley ME, Kucharczyk J. 1995. Identification of premyelination by diffusion-weighted MRI. J Comput Assist Tomogr 19:28-33.
39. Ylinen AMA, Miettinen R, Pitkanen A, Gulyas AI, Freund TF, Riekkinen PJ. 1991. Enhanced GABAnergic inhibition preserves hippocampal structure and function in a model of epilepsy. Proc Natl Acad Sci USA 88:7650-7653.